IRVINE, Calif., Aug. 03, 2017 (GLOBE NEWSWIRE) -- CombiMatrix Corporation (NASDAQ:CBMX), a family health molecular diagnostics company specializing in DNA-based reproductive health and pediatric testing services, announces financial and operating results for the three and six months ended June 30, 2017.
CombiMatrix reported total revenues for the second quarter of 2017 of $4.2 million, a 36.5% increase from $3.1 million for the second quarter of 2016.
